A randomized study of 2 risk assessment models for individualized breast cancer risk estimation

Author:

López-Fernández Adrià12ORCID,Duran-Lozano Laura1,Villacampa Guillermo3ORCID,Pardo Mónica14,Pérez Eduard12ORCID,Darder Esther5ORCID,Vallmajó Anna6ORCID,Alfonso Rosa7,Cruellas Mara12ORCID,Roqué Ariadna5ORCID,Cartró Mireia8ORCID,Bareas Adriana1,Carrasco Estela12ORCID,Rezqallah Alejandra1ORCID,Jimenez-Macedo Ana Raquel9ORCID,Torres-Esquius Sara1ORCID,Torres Maite2,Lopez Consol7,Espinosa Martín10ORCID,Teulé Alex1112ORCID,Munté Elisabet11ORCID,Tuset Noemi6ORCID,Diez Orland13,Feliubadaló Lidia1112ORCID,Lázaro Conxi1112ORCID,Llort Gemma89,Carver Tim14ORCID,Ficorella Lorenzo14ORCID,Mavaddat Nasim14ORCID,Mercadé Anna15ORCID,Antoniou Antonis C14ORCID,Brunet Joan51116ORCID,Ramon y Cajal Teresa717ORCID,Balmaña Judith12ORCID

Affiliation:

1. Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus , Barcelona,

2. Medical Oncology Department, Vall d’Hebron Barcelona Hospital Campus , Barcelona,

3. Oncology Data Science (ODysSey) Group, VHIO , Barcelona,

4. Genetic Counseling Unit, Oncology Service, Hospital del Mar , Barcelona,

5. Hereditary Cancer Program, Catalan Institute of Oncology, Josep Trueta University Hospital, IDIBGI , Girona,

6. Genetic Counseling Unit, Arnau de Vilanova University Hospital , Lleida,

7. Medical Oncology Department, Hospital de la Santa Creu i Sant Pau , Barcelona,

8. Hereditary Cancer Unit, Corporació Sanitaria Parc Taulí , Sabadell,

9. Medical Oncology Service, Consorci Sanitari de Terrassa , Terrassa,

10. Breast Surgical Unit, Vall d’Hebron Barcelona Hospital Campus , Barcelona,

11. Hereditary Cancer Program, Catalan Institute of Oncology—ICO, ONCOBELL—IDIBELL, L’Hospitalet de Llobregat ,

12. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III , Madrid,

13. Area of Clinical and Molecular Genetics, Vall d’Hebron Barcelona Hospital Campus , Barcelona,

14. Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge,

15. Servei Veterinari de Genètica Molecular (SVGM), Universitat Autonòma de Barcelona , Cerdanyola del Vallès,

16. Medical Sciences Department School of Medicine, University of Girona , Girona,

17. Medical Oncology Department, Hospital Clínic de Barcelona , Barcelona,

Abstract

Abstract Background Estimating breast cancer risk involves quantifying genetic and non-genetic factors. This supports health interventions and risk communication to ensure adherence to screening recommendations. This study evaluated the change in risk estimation when incorporating breast density and polygenic risk score (PRS) into the baseline cancer risk assessment and compared the efficacy of 2 risk-assessment delivery models. Methods This 2-step study included 663 healthy women with a family history of breast cancer in which no pathogenic variants were identified. First, breast density and PRS were added to the baseline risk assessment for all participants. A randomized intervention study compared 2 delivery models (in-person vs pre-recorded video) for risk assessment in women at moderate or average risk. All tests were 2-sided. Results Breast density and PRS reclassified the risk group into 33% of the participants, with only 5% reclassified as high-risk. After disclosure of their estimated multifactorial risk, 65% of women aligned their risk perception with their estimated risk, compared to 47% at baseline (P < .05). No statistically significant differences were found in the primary endpoint cancer worry, mean = 10.2 (SD = 3.1) vs 10.1 (2.7), between delivery models. In-person delivery had slightly better psychological outcomes (excluding the primary outcome) and higher satisfaction, though few participants in the video group sought in-person clarification. Conclusions Incorporating breast density and PRS into risk assessments led to substantial reclassification, with 1 in 5 women facing de-escalated surveillance. Personalized assessments improve objective perceptions alignment. A model using a pre-recorded video-based model matches in-person delivery for moderate and average-risk women and is scalable for population-level implementation.

Funder

Instituto de Salud Carlos III

European Union

Breast Cancer Research Foundation

Generalitat de Catalunya

Secretariat for Universities and Research of the Department of Business and Knowledge

State Agency for Research

Center of Excellence Severo Ochoa

Cellex Foundation

Cancer Research UK

PERSPECTIVE I & I

Genome Canada

Canadian Institutes of Health Research

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3